The 36-month beta value for ITOS is at 1.27. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITOS is 28.64M, and currently, shorts hold a 7.41% of that float. The average trading volume for ITOS on May 02, 2024 was 278.80K shares.
ITOS) stock’s latest price update
ITeos Therapeutics Inc (NASDAQ: ITOS) has experienced a rise in its stock price by 9.68 compared to its previous closing price of 10.74. However, the company has seen a gain of 11.45% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-01 that WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in March:
ITOS’s Market Performance
ITeos Therapeutics Inc (ITOS) has experienced a 11.45% rise in stock performance for the past week, with a -7.10% drop in the past month, and a 18.39% rise in the past quarter. The volatility ratio for the week is 4.57%, and the volatility levels for the past 30 days are at 5.07% for ITOS. The simple moving average for the past 20 days is 2.99% for ITOS’s stock, with a 5.78% simple moving average for the past 200 days.
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with H.C. Wainwright repeating the rating for ITOS by listing it as a “Buy.” The predicted price for ITOS in the upcoming period, according to H.C. Wainwright is $37 based on the research report published on May 05, 2021 of the previous year 2021.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $45. The rating they have provided for ITOS stocks is “Outperform” according to the report published on October 08th, 2020.
Wedbush gave a rating of “Outperform” to ITOS, setting the target price at $45 in the report published on August 18th of the previous year.
ITOS Trading at 3.29% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.42% of loss for the given period.
Volatility was left at 5.07%, however, over the last 30 days, the volatility rate increased by 4.57%, as shares sank -10.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.59% upper at present.
During the last 5 trading sessions, ITOS rose by +11.45%, which changed the moving average for the period of 200-days by -15.92% in comparison to the 20-day moving average, which settled at $11.37. In addition, ITeos Therapeutics Inc saw 7.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from Gall Matthew, who purchase 5,000 shares at the price of $8.37 back on Oct 12 ’23. After this action, Gall Matthew now owns 19,429 shares of ITeos Therapeutics Inc, valued at $41,850 using the latest closing price.
Boxer Capital, LLC, the of ITeos Therapeutics Inc, sale 350,000 shares at $16.26 during a trade that took place back on Aug 23 ’23, which means that Boxer Capital, LLC is holding 1,804,058 shares at $5,692,673 based on the most recent closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -11.99 for the present operating margin
- 0.93 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -8.94. The total capital return value is set at -0.24. Equity return is now at value -18.19, with -15.84 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -17.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 18.46.
Currently, EBITDA for the company is -143.99 million with net debt to EBITDA at 1.7. When we switch over and look at the enterprise to sales, we see a ratio of 14.18. The receivables turnover for the company is 1.94for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.76.
Conclusion
In conclusion, ITeos Therapeutics Inc (ITOS) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
